An interventional study of BAL-FAIOL IOL and Monofocal IOL in Cataract, sponsored by Alcon Research. Active, not recruiting at 6 sites in 4 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Alcon Research (part of Alcon) · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 116 studies in Cataract by Alcon — 4 open to participants now, 6 under way, none of them phase 3. Cataract · Alcon.
Among the 116 studies in Cataract by Alcon, this one is the 30th largest by enrollment of the 104 interventional ones that give a count, is one of 4 that started in 2023, is one of 66 with no phase, and was the 99th registered.
1,633 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →4 of the 116 studies in Cataract by Alcon are open now, in 6 countries. Recruiting first, the newest first:
Alcon Research · Sites in Australia, India, Philippines
Ages 22+
Alcon Research · Sites in United States
Ages 22+
Alcon Research · Sites in United Kingdom
Ages 18+
Alcon Research · Sites in United States, India, Philippines and 1 more country
Ages 18+
By country, each count listing its studies:
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
116 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 95 across the 104 interventional studies, 145 across the 12 observational. Of the 101 that completed or were terminated, 76 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
4 of the studies in Cataract by Alcon that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05317728Alcon ResearchClinical Study of a Fluid Accommodating Intraocular Lens (IOL) Design | 2026-11 |
| NCT06987474Alcon ResearchCapella Scientia Development Study | 2027-05 |
| NCT07228091Alcon ResearchSurgical Procedure Efficiency Evaluation stuDy | 2027-06 |
| NCT07587138Alcon ResearchClinical Evaluation of a Novel Trifocal IOL | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 116 studies in Cataract by Alcon, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to evaluate the surgical, refractive, and visual outcomes with implantation of an investigational intraocular lens (IOL).
In this study, eligible subjects will receive cataract surgery with IOL implantation in both eyes. IOL implantation in the second eye is intended to occur between 7 and 15 days after IOL implantation in the first eye. Subjects will be followed for 1 year after implantation.
This study will enroll 2 cohorts. Cohort 1 subjects will be randomized to receive either the test IOL (BAL-FAIOL) or the control IOL (Monofocal). Cohort 2 subjects will receive the test IOL only (BAL-FAIOL). Cohort 2 will follow Cohort 1.
This study will be conducted in Central America.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BAL-FAIOL IOL implanted in both eyes during cataract surgery (bilateral implantation)
Device: BAL-FAIOL IOL · Procedure: Cataract surgery
Monofocal IOL implanted in both eyes during cataract surgery (bilateral implantation)
Device: Monofocal IOL · Procedure: Cataract surgery
BAL-FAIOL IOL implanted in both eyes during cataract surgery (bilateral implantation)
Device: BAL-FAIOL IOL · Procedure: Cataract surgery
Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
Also known as: AcrySof IQ monofocal IOL (SN60WF)
Phacoemulsification with a clear cornea incision
Mean Photopic Monocular Best Corrected Distance Visual Acuity (BCDVA) (4 meters)
Distance visual acuity will be measured with correction in place for each eye individually using letter charts and recorded in logarithm Minimum Angle of Resolution (logMAR). This outcome measure is pre-specified for Cohort 1 and Cohort 2.
Time frame: Month 6 post second eye implantation
Cumulative Adverse Events, including Secondary Surgical Interventions (SSIs)
The number of adverse events, including SSI's, will be calculated from time of implantation. This outcome measure is pre-specified for Cohort 1 BAL-FAIOL IOL only.
Time frame: Up to Year 1
Cumulative Adverse Events, including Secondary Surgical Interventions (SSIs) - Cohort 2
The number of adverse events, including SSI's, will be calculated from time of implantation. The outcome measure is pre-specified for Cohort 2 only
Time frame: Up to Year 1
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Nov 2026, 44 months after the start.
Of 190 industry-sponsored interventional studies with no phase under Cataract, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's planned 44 months is above that.
Counting every sponsor, half of 493 studies reached it within 17 months; a quarter within 9 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.